Sneed P K, Gutin P H, Prados M D, Phillips T L, Weaver K A, Wara W M, Larson D A
Department of Radiation Oncology, University of California, San Francisco.
Stereotact Funct Neurosurg. 1992;59(1-4):157-65. doi: 10.1159/000098934.
Temporary implants of high-activity 125iodine sources have been used in the treatment of brain tumors since December 1979 at the University of California, San Francisco. For previously untreated patients who underwent external beam radiation therapy followed by implant boost, median survival from the date of diagnosis was 88 weeks for 34 patients with glioblastoma multiforme (GM) and 157 weeks for 29 patients with nonglioblastoma gliomas (NGM). For recurrent tumors treated with brachytherapy only, median survival from the date of the implant was 54 weeks for 45 patients with GM and 81 weeks for 50 patients with NGM. Finally, in 48 patients with recurrent tumors treated with combined hyperthermia and brachytherapy, median survival from the date of the implant was 46 weeks for 25 patients with GM and 44 weeks for 7 patients with metastases; 18-month survival was 65% for 16 patients with NGM. Brachytherapy appears to be a useful technique for the treatment of selected recurrent brain tumors and selected primary glioblastomas.
自1979年12月起，加利福尼亚大学旧金山分校就开始使用高活性125碘源临时植入物治疗脑肿瘤。对于先前未经治疗、先接受外照射放疗然后进行植入物强化治疗的患者，34例多形性胶质母细胞瘤（GM）患者从诊断之日起的中位生存期为88周，29例非胶质母细胞瘤性胶质瘤（NGM）患者为157周。对于仅接受近距离放射治疗的复发性肿瘤，45例GM患者从植入之日起的中位生存期为54周，50例NGM患者为81周。最后，在48例接受热疗和近距离放射治疗联合治疗的复发性肿瘤患者中，25例GM患者从植入之日起的中位生存期为46周，7例转移瘤患者为44周；16例NGM患者的18个月生存率为65%。近距离放射治疗似乎是治疗某些复发性脑肿瘤和某些原发性胶质母细胞瘤的一种有用技术。
